oa SA Pharmaceutical Journal - Osteoporosis - an update for the pharmacist : review
Osteoporosis is characterised by the loss of bone mass and strength caused by complex interactions among local and systemic regulators of bone cell function. Osteoporosis is classified as a bone mineral density 2.5 or more standard deviations below normal peak bone mass - that is, a T score ≤-2.5. The risk of osteoporosis is greater in women than in men and is most commonly seen in postmenopausal women resulting in fragility fractures, the risk of which increases steeply with age. Current treatments have demonstrated efficacy against vertebral and nonvertebral fractures although safety, tolerability, and cost are important considerations when choosing a therapy.
Article metrics loading...